GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.

Seeking Alpha • Aug 12, 2026

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership

GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.'

Fox Business • Aug 7, 2026

GoodRx Q2 Earnings Call Highlights

GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.

MarketBeat • Aug 6, 2026

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitability for the first six months of 2026, with revenues surging 70% to $4.9 billion.

PYMNTS • Aug 6, 2026

GoodRx Reports Second Quarter 2026 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2026. Second Quarter 2026 Highlights Revenue of $200.4 million Net income of $8.5 million; Net income margin of 4.3% Adjusted Net Income1 of $26.8 million; Adjusted Net Income Margin1 of 13.4% Adjusted EBITDA1 of $63.7 million; Adjusted EBITDA Margin1 of 3.

Business Wire • Aug 5, 2026

GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Aug 6, 2026

GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.

Zacks Investment Research • Aug 6, 2026

GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 5, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 6, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's bus.

Business Wire • Jul 9, 2026

Is GoodRx (GDRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Jul 8, 2026